CSTL Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

25.320

Open

24.670

VWAP

25.05

Vol

212.63K

Mkt Cap

762.25M

Low

24.670

Amount

5.33M

EV/EBITDA(TTM)

--

Total Shares

30.30M

EV

473.21M

EV/OCF(TTM)

7.35

P/S(TTM)

2.13

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).

Show More

Events Timeline

(ET)

2026-03-13

11:10:00

Castle Biosciences Publishes DecisionDx-Melanoma Study Results

2026-02-26 (ET)

2026-02-26

17:00:00

Company Reports Q4 Revenue of $87M Exceeding Expectations

2026-02-26

17:00:00

Castle Biosciences Sees 2026 Revenue of $340M-$350M

News

PRnewswire

11:56 AMPRnewswire

PinnedCastle Biosciences Unveils New Data on Melanoma Risk Assessment

PRnewswire

04-15PRnewswire

Castle Biosciences to Release Q1 2026 Financial Results on May 6

PRnewswire

04-10PRnewswire

Castle Biosciences Wins 2026 USA TODAY Top Workplaces Award for Fifth Year

Newsfilter

04-10Newsfilter

Castle Biosciences Wins USA TODAY Top Workplaces Award for Fifth Year

PRnewswire

03-27PRnewswire

Castle Biosciences Presents New Melanoma Survival Data at AAD 2026

Newsfilter

03-27Newsfilter

Castle Biosciences Presents New Melanoma Survival Data at AAD 2026

5 Analyst Rating

Wall Street analysts forecast CSTL stock price to rise

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

41.00

Averages

47.20

High

52.00

Current: 0.000

Low

41.00

Averages

47.20

High

52.00

Canaccord

Kyle Mikson

Buy

downgrade

$50 -> $40

AI Analysis

2026-04-20

New

Reason

Canaccord

Kyle Mikson

Price Target

$50 -> $40

AI Analysis

2026-04-20

New

downgrade

Buy

Reason

Canaccord analyst Kyle Mikson lowered the firm's price target on Castle Biosciences to $40 from $50 and keeps a Buy rating on the shares. The firm updated its model and believes the company remains a focus stocks, and they believe the company has solid operating momentum and multiple catalysts that could support long-term revenue growth.

Baird

Outperform

maintain

$41 -> $44

2026-02-27

Reason

Baird

Price Target

$41 -> $44

2026-02-27

maintain

Outperform

Reason

Baird raised the firm's price target on Castle Biosciences to $44 from $41 and keeps an Outperform rating on the shares. The firm updated its model following solid Q4 results and an outlook above consensus.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CSTL

Unlock Now

Valuation Metrics

The current forward P/E ratio for Castle Biosciences Inc (CSTL.O) is 0.00, compared to its 5-year average forward P/E of -16.06. For a more detailed relative valuation and DCF analysis to assess Castle Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-16.06

Current PE

0.00

Overvalued PE

-3.29

Undervalued PE

-28.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-5.87

Current EV/EBITDA

28.74

Overvalued EV/EBITDA

27.88

Undervalued EV/EBITDA

-39.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.00

Current PS

1.95

Overvalued PS

9.90

Undervalued PS

0.09

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stocks are due to increase 5% tomorrow

Intellectia · 11 candidates

Market Cap: >= 500.00MRegion: USList Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 60One Day Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Standex International Corp

3.30B

Oil-Dri Corporation of America

1.05B

Encore Capital Group Inc

1.63B

Johnson Outdoors Inc

534.88M

Telecom Argentina SA

4.99B

Ethan Allen Interiors Inc

564.91M

best ai stock to buy

Intellectia · 102 candidates

Revenue 5yr Cagr: >= 18Eps 5yr Cagr: >= 12Pe Ttm: <= 35

Ticker

Name

Market Cap$

eToro Group Ltd

2.56B

Brookfield Wealth Solutions Ltd

14.12B

Civitas Resources Inc

2.32B

Futu Holdings Ltd

23.11B

Dlocal Ltd

3.98B

GigaCloud Technology Inc

1.47B

list a stock with 10x potential

Intellectia · 10 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Weekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Figs Inc

1.90B

Dream Finders Homes Inc

1.83B

Merchants Bancorp

1.64B

Xpel Inc

1.52B

Arhaus Inc

1.49B

GigaCloud Technology Inc

1.47B

stocks that will rise the most by 2026

Intellectia · 17 candidates

Revenue 5yr Cagr: >= 25Eps 5yr Cagr: >= 25Pe Ttm: <= 25Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

Monolithic Power Systems Inc

51.50B

Futu Holdings Ltd

23.11B

Genmab A/S

20.30B

Super Micro Computer Inc

19.25B

Kaspi.kz AO

14.51B

Kinsale Capital Group Inc

9.43B

which stocks should short sell

Intellectia · 2 candidates

Short Ratio: LessThan10PctBeta: HighRiskRsi 14: >= 60Month Price Change Pct: $-100.00 - $0.00

Ticker

Name

Market Cap$

Castle Biosciences Inc

1.20B

Standard BioTools Inc

630.69M

small cap stocks anticipating 20-30% growth

Intellectia · 8 candidates

Market Cap: 300.00M - 2.00BRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

GigaCloud Technology Inc

1.47B

Vital Farms Inc

1.22B

Castle Biosciences Inc

1.20B

LuxExperience BV

1.14B

Nuveen Churchill Direct Lending Corp

677.59M

Tiptree Inc

654.35M

small cap , growth

Intellectia · 18 candidates

Market Cap: 300.00M - 2.00BRevenue 5yr Cagr: >= 10Eps 5yr Cagr: >= 10Pe Ttm: <= 30Annual Revenue Yoy Growth: >= 15.0%

Ticker

Name

Market Cap$

Costamare Inc

1.91B

Dream Finders Homes Inc

1.83B

Merchants Bancorp

1.64B

GigaCloud Technology Inc

1.47B

Vital Farms Inc

1.22B

Opera Ltd

1.21B

Next stock that will 100x

Intellectia · 7 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 20

Ticker

Name

Market Cap$

Dream Finders Homes Inc

1.83B

Merchants Bancorp

1.64B

GigaCloud Technology Inc

1.47B

Opera Ltd

1.21B

Castle Biosciences Inc

1.20B

Inmode Ltd

892.51M

Best stocks to 1000x in future

Intellectia · 21 candidates

Market Cap: <= 5.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20

Ticker

Name

Market Cap$

Crocs Inc

4.43B

St Joe Co

3.75B

Paymentus Holdings Inc

3.63B

ACM Research Inc

3.47B

Fortuna Mining Corp

3.30B

Banc of California Inc

3.28B

Best stock with future potential 100x

Intellectia · 7 candidates

Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 20

Ticker

Name

Market Cap$

Dream Finders Homes Inc

1.83B

Merchants Bancorp

1.64B

GigaCloud Technology Inc

1.47B

Opera Ltd

1.21B

Castle Biosciences Inc

1.20B

Inmode Ltd

892.51M

Whales Holding CSTL

Summit Partners Public Asset Management, LLC

RTW Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Castle Biosciences Inc (CSTL) stock price today?

The current price of CSTL is 25.16 USD — it has increased 0.44

What is Castle Biosciences Inc (CSTL)'s business?

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).

What is the price predicton of CSTL Stock?

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is47.20 USD with a low forecast of 41.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Castle Biosciences Inc (CSTL)'s revenue for the last quarter?

Castle Biosciences Inc revenue for the last quarter amounts to 87.01M USD, increased 0.81

What is Castle Biosciences Inc (CSTL)'s earnings per share (EPS) for the last quarter?

Castle Biosciences Inc. EPS for the last quarter amounts to -0.08 USD, decreased -125.81

How many employees does Castle Biosciences Inc (CSTL). have?

Castle Biosciences Inc (CSTL) has 883 emplpoyees as of April 21 2026.

What is Castle Biosciences Inc (CSTL) market cap?

Today CSTL has the market capitalization of 762.25M USD.